---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324865"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2026-07-30T11:05:07+00:00"
generated_at: "2026-07-30T11:10:45.999103+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phathom Q2 revenue $74.3M (+88% YoY); net loss narrows to $17.6M; initiates Phase 3 NERD trial

## Summary
- Record Q2 net revenue $74.3M, up 88% YoY and 27% QoQ; operating expenses $63.1M, down 33% YoY.
- Net loss $17.6M vs $75.8M in Q2 2025; non-GAAP adjusted net loss nearly zero at $0.1M.
- ~325,000 VOQUEZNA prescriptions in Q2 (+88% YoY); ~1.7M total to date.
- Initiating Phase 3 trial for as-needed VOQUEZNA in NERD; first enrollment expected Q4 2026.
- Completed enrollment in Phase 2 EoE trial; topline results expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-324865
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2026-07-30T11:05:07+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/0001193125-26-324865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324865
- JSON: https://secwatch.observer/filing/0001193125-26-324865.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.